#United States #Tempe #GammaTile #GT Medical Technologies #brain tumor care

GT Medical Technologies Reaches an Impressive Milestone

GT Medical Technologies has announced a significant clinical achievement: the treatment of 2,000 patients with their innovative product, GammaTile®, designed specifically for brain tumors. This milestone was reached at the Jersey Shore University Medical Center, which has become a recognized GammaTile Center of Excellence. This achievement underscores the growing adoption of GammaTile in various leading cancer hospitals throughout the United States.

Since its introduction to the market in March 2020, GammaTile has been embraced by over 200 esteemed cancer centers and hospitals nationwide. This FDA-cleared device is a bioresorbable implant that delivers targeted radiation therapy right after a tumor is surgically removed, which is a game-changer in the treatment of operable brain tumors.

Per Langoe, the CEO of GT Medical Technologies, stated that treating 2,000 patients represents more than just a numerical milestone; it signifies ongoing progress in combatting brain tumors, which historically see a recurrence in 50% of cases. He emphasized that this achievement demonstrates the company’s unwavering commitment to expanding treatment options and enhancing care for patients facing operable brain tumors.

How GammaTile Works

GammaTile is a sophisticated form of radiation therapy that offers immediate treatment during the surgical procedure. By placing the implant at the site of the tumor removal, it sends localized radiation precisely when residual cancer cells are most vulnerable. This contrasts sharply with traditional approaches that often necessitate a waiting period between surgery and radiation treatment, allowing for potential tumor regrowth during that time.

Dr. Nitesh Patel, a neurosurgeon at Jersey Shore University Medical Center, remarked on the transformative potential of GammaTile, stating that it fundamentally changes how effective local control can be in brain tumor management. By providing radiation directly at the tumor's margins, GammaTile increases the likelihood of successful outcomes and longevity in cancer care.

GT Medical Technologies Commitment

Founded by a team of specialists in brain tumors, GT Medical Technologies aims to fulfill the pressing needs in brain tumor treatment. The company's mission is to enhance the lives of individuals battling these devastating conditions through innovative healthcare solutions that redefine care standards.

GammaTile stands out as a pioneering product in the realm of brain surgery, designed to release radiation seeds embedded within a FDA-approved bioabsorbable collagen implant. By administering treatment from within, it minimizes exposure to surrounding healthy brain tissue while targeting the weakest cancer cells, helping to prevent regrowth.

Since its launch, GammaTile has made remarkable strides, being adopted by more than 100 leading medical centers. This growing acceptance reflects both its effectiveness and the increasing acknowledgment of the treatment within both academic and community healthcare settings.

For anyone affected by brain tumors, the progress achieved by GT Medical Technologies and GammaTile offers a beacon of hope. More information can be found via their official site at gammatile.com and on various social media platforms including Facebook, Instagram, and LinkedIn.

Conclusion

As GT Medical Technologies celebrates this important milestone, the focus continues on broadening access to innovative treatment options for brain tumor patients. GammaTile’s effectiveness demonstrates a significant advancement in this vital area of healthcare and speaks to a promising future in brain tumor management for healthcare professionals and patients alike.